The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
The Multiple Myeloma Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Gold) and Legend Biotech (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2023 | Outpatient monitoring following CAR-T and BsAb treatment for patients with lymphoma and MM
Yi Lin, MD, PhD, Mayo Clinic, Rochester, MN, discusses an outpatient monitoring model for patients undergoing CAR-T or bispecific antibody (BsAb) treatment for lymphoma and multiple myeloma (MM). The approach integrates home health visits and tocilizumab administration to manage potential cytokine release syndrome (CRS) and reduce the number of visits to the clinic or hospital. Successfully trialled in 18 patients, 17 have remained outpatient without clinic admission, with high patient satisfaction reported. This interview took place at the 65th ASH Annual Meeting and Exposition, held in San Diego, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
